acyclovir and Erythema-Multiforme

acyclovir has been researched along with Erythema-Multiforme* in 46 studies

Reviews

9 review(s) available for acyclovir and Erythema-Multiforme

ArticleYear
Interventions for erythema multiforme: a systematic review.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:5

    Treatment of erythema multiforme (EM) is not codified. We performed a systematic review of the effect of any topical or systemic treatment on time to healing and frequency of episodes with acute and chronic forms of EM in adults. Four databases (MEDLINE, CENTRAL, EMBASE and LILACS) and other sources were searched for articles published up to 20 March 2018. Randomized control trials (RCTs), observational studies and case series (n ≥ 10) were considered. From 1558 references, we included one RCT and six case series. The RCT (n = 20) showed a significant difference in complete remission of EM with continuous acyclovir vs. placebo over 6 months. One case series found a mean reduction in flare duration with thalidomide for recurrent EM (5.1 vs. 16.2 days; n = 20). Adverse events were poorly or not reported in included studies. Quality of life was never assessed. One limitation of our study is that we excluded the cases of isolated mucosal EM in order to prevent inclusion of Stevens-Johnson syndrome cases. In conclusion, there is low-level evidence for continuous acyclovir treatment for recurrent EM (one RCT). Evidence for other treatments is only based on retrospective case series. Results for thalidomide, in particular, encourage further research. Data concerning safety are insufficient. PROSPERO registration no. CRD42016053175.

    Topics: Acyclovir; Adult; Erythema Multiforme; Female; Humans; Male; Placebos; Retrospective Studies

2019
Current Perspectives on Erythema Multiforme.
    Clinical reviews in allergy & immunology, 2018, Volume: 54, Issue:1

    Recognition and timely adequate treatment of erythema multiforme remain a major challenge. In this review, current diagnostic guidelines, potential pitfalls, and modern/novel treatment options are summarized with the aim to help clinicians with diagnostic and therapeutic decision-making. The diagnosis of erythema multiforme, that has an acute, self-limiting course, is based on its typical clinical picture of targetoid erythematous lesions with predominant acral localization as well as histological findings. Clinically, erythema multiforme can be differentiated into isolated cutaneous and combined mucocutaneous forms. Atypical erythema multiforme manifestations include lichenoid or granulomatous lesions as well as lesional infiltrates of T cell lymphoma and histiocytes. Herpes simplex virus infection being the most common cause, other infectious agents like-especially in children-Mycoplasma pneumoniae, hepatitis C virus, Coxsackie virus, and Epstein Barr virus may also trigger erythema multiforme. The second most frequently identified cause of erythema multiforme is drugs. In different studies, e.g., allopurinol, phenobarbital, phenytoin, valproic acid, antibacterial sulfonamides, penicillins, erythromycin, nitrofurantoin, tetracyclines, chlormezanone, acetylsalicylic acid, statins, as well as different TNF-α inhibitors such as adalimumab, infliximab, and etanercept were reported as possible implicated drugs. Recently, cases of erythema multiforme associated with vaccination, immunotherapy for melanoma, and even with topical drugs like imiquimod have been described. In patients with recurrent herpes simplex virus-associated erythema multiforme, the topical prophylactic treatment with acyclovir does not seem to prevent further episodes of erythema multiforme. In case of resistance to one virostatic drug, the switch to an alternative drug, and in patients non-responsive to virostatic agents, the use of dapsone as well as new treatment options, e.g., JAK-inhibitors or apremilast, might be considered.

    Topics: Acyclovir; Dapsone; Drug-Related Side Effects and Adverse Reactions; Erythema Multiforme; Herpes Simplex; Histiocytes; Humans; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Practice Guidelines as Topic; Simplexvirus; Skin; T-Lymphocytes; Thalidomide

2018
Management of recurrent oral herpes simplex infections.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103 Suppl

    The literature has been reviewed for evidence of the efficacy of antiviral agents in both the prophylaxis and treatment of recurrent oral herpes simplex virus (HSV) infections and discussed by a panel of experts. Emphasis was given to randomized controlled trials. Management of herpes-associated erythema multiforme and Bell palsy were also considered. The evidence suggests that 5% acyclovir (ACV) in the cream base may reduce the duration of lesions if applied early. Recurrent herpes labialis (RHL) and recurrent intraoral HSV infections can be effectively treated with systemic ACV 400 mg 3 times a day or systemic valacyclovir 500 to 1000 mg twice a day for 3 to 5 days (longer in the immunocompromised). RHL in the immunocompetent can be effectively prevented with (1) sunscreen alone (SPF 15 or above), (2) systemic ACV 400 mg 2 to 3 times a day, or (3) systemic valacyclovir 500 to 2000 mg twice a day. Valacyclovir 500 mg twice a day is also effective in suppressing erythema multiforme triggered by HSV. Further studies are needed to compare treatment efficacy between topical penciclovir, docosanol, and ACV cream for RHL.

    Topics: Acyclovir; Antiviral Agents; Bell Palsy; Cidofovir; Cytosine; Erythema Multiforme; Herpes Labialis; Humans; Immunocompromised Host; Organophosphonates; Secondary Prevention; Sunscreening Agents; Time Factors; Valacyclovir; Valine

2007
Erythema multiforme.
    American family physician, 2006, Dec-01, Volume: 74, Issue:11

    Erythema multiforme is a skin condition considered to be a hypersensitivity reaction to infections or drugs. It consists of a polymorphous eruption of macules, papules, and characteristic "target" lesions that are symmetrically distributed with a propensity for the distal extremities. There is minimal mucosal involvement. Management involves treating the existing infectious agent or discontinuing the causal drug. Mild cases resolve without sequelae and do not require treatment. Recurrent cases have been prevented with continuous acyclovir. Patients who have no response to acyclovir may have a response to valacyclovir or famcilovir, which have greater oral bioavailability and more convenient dosing. Patients with recurrent erythema multiforme despite suppressive antiviral therapy should be referred to a dermatologist for further treatment.

    Topics: Acyclovir; Antiviral Agents; Diagnosis, Differential; Erythema Multiforme; Humans

2006
Erythema multiforme due to herpes simplex virus. Recurring target lesions are the clue to diagnosis.
    Postgraduate medicine, 1999, Oct-15, Volume: 106, Issue:5

    Topics: Acyclovir; Aged; Antiviral Agents; Erythema Multiforme; Herpes Simplex; Humans; Male; Recurrence; Skin

1999
[Recurrent erythema multiforme and herpes simplex virus infection].
    Annales de dermatologie et de venereologie, 1992, Volume: 119, Issue:4

    Topics: Acyclovir; Adult; Erythema Multiforme; Herpes Simplex; Humans; Recurrence

1992
Erythema multiforme minor in children.
    Pediatrician, 1991, Volume: 18, Issue:3

    Erythema multiforme minor is an acute, self-limited cutaneous or mucocutaneous disorder. Although it most commonly afflicts young adults, it is also frequently seen in children. An antecedent infection with herpes simplex virus is often the precipitating factor. Recent studies detailing the usual clinical course and histologic features of erythema multiforme minor, together with investigative studies examining potential pathomechanisms, have begun to provide a clearer picture of this disease process such that a more rational approach to therapy is now possible.

    Topics: Acyclovir; Adolescent; Adult; Age Factors; Child; Child, Preschool; Diagnosis, Differential; Erythema Multiforme; Herpes Simplex; Humans; Infant

1991
Therapy and prevention of erythema multiforme with acyclovir.
    Seminars in dermatology, 1988, Volume: 7, Issue:3

    Topics: Acyclovir; Antigen-Antibody Reactions; Drug Administration Schedule; Erythema Multiforme; Herpesviridae Infections; Humans; Recurrence; Skin

1988
Management of non-genital herpes simplex virus infections in immunocompetent patients.
    The American journal of medicine, 1988, Aug-29, Volume: 85, Issue:2A

    Non-genital herpes simplex virus in immunocompetent hosts causes a variety of primary infections--gingivostomatitis, keratoconjunctivitis, herpetic whitlow, and encephalomyelitis. Recurrent infections with orolabialis are very common, but are usually mild and self-limiting. Cutaneous complications of herpes simplex virus infections include eczema herpeticum and erytherma multiforme. Systemic treatment with acyclovir is indicated in encephalomyelitis, progressive eczema herpeticum, and frequent severe erythema multiforme. Chronic, suppressive acyclovir treatment may be helpful in severe recurrent infections or those complicated by erythema multiforme/dissemination. Many primary and recurrent infections can be treated with simple topical therapy to control secondary infection. There is no evidence that systemic treatment affects viral latency or recurrent infections following discontinuation of treatment.

    Topics: Acyclovir; Erythema Multiforme; Herpes Simplex; Humans; Idoxuridine; Immunity; Kaposi Varicelliform Eruption; Recurrence; Vaccination

1988

Trials

2 trial(s) available for acyclovir and Erythema-Multiforme

ArticleYear
A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme.
    The British journal of dermatology, 1995, Volume: 132, Issue:2

    Twenty patients who suffered from more than four attacks of erythema multiforme (EM) per year were enrolled in a 6-month double-blind, placebo-controlled trial of acyclovir 400 mg twice daily. Fifteen patients had disease precipitated by recurrent herpes simplex. In the acyclovir-treated group the median number of EM attacks during the treatment period was zero, compared with three in the placebo-treated group (P < 0.0005, Wilcoxon rank sum test). Seven of the 11 patients treated with continuous acyclovir did not have any attacks of EM while taking the drug, and one showed almost complete disease suppression. Following treatment with acyclovir, two patients went into complete remission, whereas all individuals in the placebo group continued to have attacks. In the acyclovir-treated group nine of the 11 patients had herpes simplex-precipitated disease. One of the two patients with idiopathic disease showed complete disease suppression while on acyclovir, lending support to the view that idiopathic recurrent EM may be related to subclinical herpetic infection. In this study, we have shown that continuous acyclovir therapy can completely suppress attacks of recurrent EM and, in some cases, may induce disease remission.

    Topics: Acyclovir; Adult; Aged; Double-Blind Method; Erythema Multiforme; Female; Herpes Simplex; Humans; Male; Middle Aged; Recurrence

1995
Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme.
    British medical journal (Clinical research ed.), 1983, Sep-17, Volume: 287, Issue:6395

    Topics: Acyclovir; Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Erythema Multiforme; Herpes Simplex; Humans; Recurrence

1983

Other Studies

35 other study(ies) available for acyclovir and Erythema-Multiforme

ArticleYear
Recurrent erythema multiforme: A therapeutic proposal for a chronic disease.
    The Journal of dermatology, 2021, Volume: 48, Issue:10

    Recurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical-epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty-five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow-up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2-6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long-term therapeutic protocol to enable disease remission.

    Topics: Acyclovir; Adult; Chronic Disease; Erythema Multiforme; Female; Herpes Simplex; Humans; Recurrence; Retrospective Studies

2021
Efficacy of interferon in recurrent valaciclovir-refractory erythema multiforme in a patient not infected with hepatitis C virus.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:6

    Recurrent erythema multiforme (EM) is rare and is most typically related to infections with herpes simplex virus. Prophylactic administration of valaciclovir is the first-line treatment, but there is no agreement about second-line treatment in cases of ineffectiveness. We present a 31-year-old man who was not infected with hepatitis C virus (HCV), and had a history of severe and recurrent EM, unresponsive to valaciclovir, colchicine and hydroxychloroquine. The patient noticed that an intermittent flu-like illness seemed to have abrogated an EM flare. Because of this observation, the next EM flares were treated with short courses of interferon, which gave rapid and complete efficacy. Efficacy of interferon in EM has only been reported in two previous patients, in whom the drug was administered to treat HCV infection. Efficiency was attributed to treatment of the underlying HCV infection, which was thought to be the origin of EM in both cases. This is the first case, to our knowledge, reporting a dramatic response to interferon-alfa in a patient who was not infected with HCV.

    Topics: Acyclovir; Adult; Antiviral Agents; Erythema Multiforme; Herpes Simplex; Humans; Immunologic Factors; Interferon-alpha; Male; Mouth Mucosa; Rare Diseases; Treatment Outcome; Valacyclovir; Valine

2016
Eruption of Eyelid Target Lesions.
    JAMA ophthalmology, 2016, 10-01, Volume: 134, Issue:10

    Topics: Acyclovir; Administration, Oral; Antiviral Agents; Child; Erythema Multiforme; Eye Infections, Viral; Eyelid Diseases; Herpes Simplex; Herpesvirus 1, Human; Humans; Male

2016
Erythema Multiforme.
    The Journal of emergency medicine, 2015, Volume: 49, Issue:6

    Topics: Acyclovir; Adult; Anesthetics, Local; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Erythema Multiforme; Female; Glucocorticoids; Humans; Lidocaine; Methylprednisolone; Recurrence; Valacyclovir; Valine

2015
Herpes-associated erythema multiforme worsened by a Siddha drug, Alpinia galanga, in an 18-year-old man.
    BMJ case reports, 2015, Sep-21, Volume: 2015

    Topics: Acyclovir; Adolescent; Alpinia; Antiviral Agents; Erythema Multiforme; Herpes Simplex; Humans; Lip; Male; Medicine, Ayurvedic; Plant Preparations; Ulcer

2015
The use of corticosteroids in management of Herpes associated Erythema Multiforme.
    JPMA. The Journal of the Pakistan Medical Association, 2015, Volume: 65, Issue:12

    Erythema multiforme (EM) is an acute self-limiting condition considered to be hypersensitivity reaction associated commonly with infections or medications. It is characterized by skin lesions, with oral or other mucous membrane involvement. Occasionally EM may involve the mouth alone. We report a ten year-old healthy male child who developed skin lesions of both palms and soles associated with oral ulcerative lesions. The patient first noticed the lesions on the palms and soles followed by involvement of the oral cavity in form of multiple haemorrhagic crusting ulcerations involving lips and buccal mucosa. The diagnosis was established clinically based on the signs and symptoms as erythema multiforme minor associated with herpes simplex infection. Systemic corticosteroids as a treatment modality should always be considered for the treatment of erythema multiforme minor.

    Topics: Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Child; Erythema Multiforme; Herpes Simplex; Humans; Hydrocortisone; Male

2015
Oral ulcers and targetoid lesions on the palms.
    JAMA, 2014, Mar-19, Volume: 311, Issue:11

    Topics: Acyclovir; Antiviral Agents; Diagnosis, Differential; Erythema Multiforme; Gram-Negative Bacterial Infections; Hand; Herpes Simplex; Humans; Male; Mycoplasma pneumoniae; Oral Ulcer; Simplexvirus; Valacyclovir; Valine; Young Adult

2014
Education and imaging: gastrointestinal: herpes simplex virus-associated erythema multiforme (HAEM) during infliximab treatment for ulcerative colitis.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:3

    Topics: Acyclovir; Antibodies, Monoclonal; Antiviral Agents; Colitis, Ulcerative; Colonic Pouches; Erythema Multiforme; Female; Gastrointestinal Agents; Herpes Simplex; Humans; Ileostomy; Immunosuppressive Agents; Infliximab; Proctocolectomy, Restorative; Simplexvirus; Treatment Outcome; Valacyclovir; Valine; Virus Activation; Young Adult

2011
Two takes on Turkish targets.
    Journal of the Royal Naval Medical Service, 2009, Volume: 95, Issue:2

    Topics: Acyclovir; Antiviral Agents; Diagnosis, Differential; Erythema Multiforme; Herpes Simplex; Herpesvirus 1, Human; Humans; Immunosuppressive Agents; Male; Military Personnel; Triamcinolone Acetonide; Turkey; United Kingdom; Young Adult

2009
Management of erythema multiforme associated with recurrent herpes infection: a case report.
    Journal (Canadian Dental Association), 2009, Volume: 75, Issue:8

    Erythema multiforme is an acute mucocutaneous disorder, characterized by varying degrees of blistering and ulceration. We report a case of recurrent herpes-associated erythema multiforme managed with prophylactic acyclovir. An 11-year-old boy had lesions in the oral cavity and lips, which had been diagnosed as erythema multiforme minor. Four months later, the patient had desquamative gingivitis with erythematous lesions and necrotic areas in the skin. This episode was not related to drug intake, which suggests that the erythema multiforme was a result of herpetic infection. This hypothesis was supported by positive serology for herpes simplex virus. Five months later, the patient returned with new oral, skin and penis mucosal lesions. The diagnosis was confirmed as herpes simplex virus-associated erythema multiforme major. The episode was treated with acyclovir, and acyclovir was used prophylactically for 7 months to control the disease.

    Topics: Acyclovir; Antiviral Agents; Child; Erythema Multiforme; Follow-Up Studies; Gingivitis; Herpes Genitalis; Herpes Labialis; Humans; Lip Diseases; Male; Mouth Diseases; Penile Diseases; Recurrence; Simplexvirus; Stomatitis, Herpetic

2009
Erythema multiforme presenting as chronic oral ulceration due to unrecognised herpes simplex virus infection.
    Clinical and experimental dermatology, 2006, Volume: 31, Issue:5

    Topics: Acyclovir; Administration, Oral; Antiviral Agents; Erythema Multiforme; Female; Herpes Simplex; Humans; Middle Aged; Oral Ulcer; Recurrence; Treatment Outcome

2006
[Erythema multiforme majus and Chlamydia pneumoniae infection].
    Annales de dermatologie et de venereologie, 2006, Volume: 133, Issue:12

    Erythema multiforme majus of infectious origin is an acute eruptive syndrome seen more commonly in young subjects and characterised by an appearance of round target lesions. In most cases, it is associated with infection involving Herpes simplex virus or Mycoplasma pneumoniae. We report an original case of erythema multiforme majus subsequent to infection with Chlamydia pneumoniae.. An 18 year-old man was hospitalised for management of generalised skin rash comprising lesions in rings, associated with bullous and post-bullous lesions, chiefly in the oral (preventing eating) and genital areas in a setting of febrile cough. Various bacterial agents (Mycoplasma pneumoniae, Chlamydia pneumoniae) and viral agents were suspected, but serological testing for Chlamydia pneumoniae alone was positive with IgM of 128 IU and IgG of 64 IU. The outcome was favourable within several days following administration of symptomatic treatment (rehydration, mouthwashes, etc.) and aetiological treatment (acyclovir: 30 mg/kg/d, ofloxacine: 400 mg/d). At D15, serologic tests for Mycoplasma pneumoniae continued to be negative. Anti-Chlamydia pneumoniae IgM and IgG were 256 IU. At D30, IgM was 128 IU while IgG remained at 256 IU.. The existence of a systematic skin rash comprising typical target lesions and mucosal lesions in the oral and genital areas suggested to us a diagnosis of erythema multiforme majus. Screening for the agents generally responsible was negative and drug-induced rash was ruled out. Serological tests for Chlamydia pneumoniae were positive at various times, resulting in diagnosis of erythema multiforme majus secondary to infection with Chlamydia pneumoniae. Following demonstration of the presence of Chlamydia pneumoniae using reliable methods and the elimination of other causes of erythema multiforme majus, dermatologists should opt for this aetiology in order to optimise treatment.

    Topics: Acyclovir; Adolescent; Anti-Bacterial Agents; Antiviral Agents; Chlamydophila Infections; Chlamydophila pneumoniae; Erythema Multiforme; Humans; Male; Ofloxacin

2006
Cases from the Osler Medical Service at Johns Hopkins University.
    The American journal of medicine, 2004, Mar-01, Volume: 116, Issue:5

    Topics: Acyclovir; Adult; Antiviral Agents; Diagnosis, Differential; Erythema Multiforme; Estrogen Replacement Therapy; Female; Herpes Simplex; Humans; Valacyclovir; Valine

2004
Arthritis associated with recurrent erythema multiforme responding to oral acyclovir.
    Clinical rheumatology, 2002, Volume: 21, Issue:5

    Erythema multiforme is a skin condition frequently associated with herpes simplex virus and has a tendency to recur. Oral acyclovir has been successful in suppression of the disease. Here we report a patient who had recurrent erythema multiforme associated with recurrent polyarthritis that responded to oral acyclovir suppression therapy.

    Topics: Acyclovir; Administration, Oral; Adult; Arthritis; Biopsy, Needle; Drug Therapy, Combination; Erythema Multiforme; Follow-Up Studies; Humans; Indomethacin; Male; Recurrence; Severity of Illness Index; Treatment Outcome

2002
Erythema multiforme secondary to herpes simplex infection: a case report.
    Journal of periodontology, 2001, Volume: 72, Issue:7

    Erythema multiforme (EM) is a complex disease that may have cutaneous and/or mucosal involvement. The severity may range from mild to severe and potentially life threatening. The literature cites many factors including viruses, infections, and medications as causes. This report documents a patient who developed EM secondary to a herpes simplex viral (HSV) infection.. Two weeks following an eruption of herpes labialis, a 20-year-old white female patient developed acutely painful oral and labial ulcers accompanied by target skin lesions. A diagnosis of erythema multiforme (EM) was made. The patient was treated with antivirals, analgesics, and symptomatic therapy.. Nine days after the onset of symptoms, the oral and cutaneous lesions had started to heal and the patient no longer required pain medication.. Although the etiology of EM is still often unknown, infections with herpes simplex virus have been implicated as a possible precipitating factor. This case illustrates the association of the occurrence of EM with an HSV infection.

    Topics: Acyclovir; Adult; Analgesics; Antiviral Agents; Erythema Multiforme; Female; Gingival Diseases; Herpes Labialis; Humans; Lip Diseases; Oral Ulcer; Recurrence; Stomatitis, Herpetic; Wound Healing

2001
Recurrent erythema multiforme in a child.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2000, Volume: 6, Issue:3

    Topics: Acyclovir; Antiviral Agents; Child; Erythema Multiforme; Herpes Labialis; Humans; Male; Recurrence

2000
Erythema multiforme: a case with unusual histopathological features.
    The Australasian journal of dermatology, 2000, Volume: 41, Issue:4

    A 14-year-old boy presented with widespread cutaneous and mucosal lesions clinically consistent with erythema multiforme. He gave a history of previous episodes of a similar eruption. Histological examination of a representative lesion showed changes consistent with erythema multiforme. It also, however, contained large numbers of eosinophils, forming a dermal interstitial infiltrate and epidermal microabscesses. The full blood examination showed a persistent eosinophilia. The appearances initially confused two experienced dermatopathologists.

    Topics: Acyclovir; Adolescent; Biopsy, Needle; Drug Therapy, Combination; Erythema Multiforme; Fluorescent Antibody Technique, Direct; Follow-Up Studies; Humans; Male; Prednisolone

2000
Atypical forms of herpes simplex-associated erythema multiforme.
    Journal of the American Academy of Dermatology, 1998, Volume: 39, Issue:1

    Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; DNA, Viral; Erythema Multiforme; Female; Follow-Up Studies; Herpes Labialis; Herpes Simplex; Humans; Simplexvirus

1998
Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy.
    Archives of dermatology, 1998, Volume: 134, Issue:7

    Topics: Acyclovir; Adult; Antiviral Agents; Erythema Multiforme; Humans; Male; Prodrugs; Recurrence; Time Factors; Treatment Outcome; Valacyclovir; Valine

1998
Bullous erythema multiforme following herpes zoster and varicella-zoster virus infection.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 1998, Volume: 11, Issue:2

    Four cases of herpes zoster-induced bullous erythema multiforme (EM) are reported. Three patients presented with widespread skin lesions 10 to 14 days after an episode of thoracic herpes zoster. In these patients a high increase in varicella-zoster virus (VZV) antibody titer was detected, indicating secondary VZV infection. Histologic examinations of skin biopsy from a patient with widespread lesions (case 4) revealed a mixture of EM, toxic epidermal necrolysis and herpetic virus infection. VZV should be included in the list of infectious agents able to trigger EM and Stevens-Johnson syndrome.

    Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Erythema Multiforme; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Skin

1998
[Recurrent postherpetic erythema multiforme presenting as a polymorphous light eruption and 'juvenile spring eruption].
    Nederlands tijdschrift voor geneeskunde, 1998, Dec-05, Volume: 142, Issue:49

    Topics: Acyclovir; Antiviral Agents; Child; Diagnosis, Differential; Erythema Multiforme; Herpes Labialis; Herpesviridae Infections; Humans; Light; Male; Photosensitivity Disorders; Sunscreening Agents; Treatment Outcome

1998
Herpes simplex virus-associated erythema multiforme in prepubertal children.
    Archives of pediatrics & adolescent medicine, 1997, Volume: 151, Issue:10

    To examine clinical associations, evolution of the condition, and response to treatment of erythema multiforme (EM) in prepubertal children.. A retrospective case series evaluation of children younger than 13 years with EM.. Ambulatory care university hospital.. Referral patients from pediatricians serving a population of 3.2 million.. Results of treatment of each EM episode with topical acyclovir or oral acyclovir at a dose of 25 mg/kg per day and 6-month prophylaxis with oral acyclovir at a dose of 20 mg/kg per day were evaluated.. Age at EM onset, preceding illness, and number and duration of episodes during a 3-year period were recorded.. Twelve children (7 boys and 5 girls) in whom herpes simplex virus (HSV)-associated EM developed were evaluated. Preceding lesions were herpes labialis in 8 children and herpes facialis in 2 children. Two children had no obvious HSV lesion. The mean age at onset of disease was 8.1 years, and the mean time from the preceding HSV to the onset of skin lesions was 3.9 days (range, 0-11 days). Episodes of EM lasted a mean of 10.6 days. In 9 children, the EM was recurrent, with a mean of 2.6 episodes per year. All 12 children, including those with negative viral cultures for HSV or no HSV history had HSV detected in their target lesions by polymerase chain reaction amplification of DNA obtained from skin biopsy specimens. Six of 12 children were treated with oral acyclovir at a dose of 25 mg/kg per day for 1 or more individual episodes, without reduction in the episode. Three children underwent 6-month prophylaxis with oral acyclovir at a dose of 20 mg/kg per day and remained disease free during treatment. After discontinuation of the prophylactic treatment with acyclovir, 1 child relapsed at 4 months. The other 2 children had no further episodes during a 3-year period.. The HSV-associated EM is a recurrent disease that can be precipitated by sun exposure and does not progress to Stevens-Johnson syndrome. Childhood HSV-associated EM may be unresponsive to treatment with oral steroids or oral or topical acyclovir. Frequent recurrences of EM may be abrogated by prophylactic treatment with acyclovir.

    Topics: Acyclovir; Antiviral Agents; Child; Disease Progression; Erythema Multiforme; Female; Herpes Simplex; Humans; Male; Polymerase Chain Reaction; Recurrence; Referral and Consultation; Retrospective Studies; Sunlight; Time Factors; Treatment Outcome

1997
A case of herpes-associated erythema multiforme in a Japanese child.
    The Journal of dermatology, 1993, Volume: 20, Issue:8

    A case of a five-year-old Japanese boy with herpes-associated erythema multiforme (HAEM) was reported. The patient had eleven recurrences of herpes labiaris within one year; four of these recurrences were accompanied by erythema multiforme. A study of the human leukocyte antigens revealed the presence of HLA-DQW3, which has been reported to be significantly frequent in Caucasian patients with HAEM. Oral administration of acyclovir at the onset of herpes labialis was effective in preventing HAEM. Early administration of oral steroids at the onset of HAEM also prevented its exacerbation.

    Topics: Acyclovir; Administration, Oral; Asian People; Betamethasone; Child, Preschool; Erythema Multiforme; Herpes Labialis; HLA-DQ Antigens; Humans; Japan; Male; Recurrence; Skin

1993
Recurrent erythema multiforme: clinical features and treatment in a large series of patients.
    The British journal of dermatology, 1993, Volume: 128, Issue:5

    Recurrent erythema multiforme is an uncommon disorder. We have reviewed the clinical features and treatment of 65 patients with this condition. The mean number of attacks per year was six (range 2-24), and the mean duration of the disease was 9.5 years (range 2-36) reflecting its chronicity. The majority of patients had oral mucous membrane involvement (69%). In 46 patients (71%) the condition was precipitated by a preceding herpes simplex virus infection. Acyclovir was found to be the most useful first-line treatment, with 55% of patients deriving benefit from either continuous oral acyclovir or a patient-initiated 5-day oral course at the onset of herpes simplex virus infection. Of those failing to respond to acyclovir, a small proportion responded to dapsone. The most resistant patients (11) were treated with azathioprine, with complete disease suppression in all cases.

    Topics: Acyclovir; Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Administration Schedule; Erythema Multiforme; Female; Herpes Simplex; Humans; Immunization, Passive; Immunoglobulins; Infant; Male; Middle Aged; Recurrence

1993
Very low dose acyclovir can be effective as prophylaxis for post-herpetic erythema multiforme.
    The British journal of dermatology, 1991, Volume: 124, Issue:1

    Topics: Acyclovir; Adult; Erythema Multiforme; Female; Herpes Simplex; Humans

1991
Acyclovir for recurrent erythema multiforme caused by herpes simplex.
    Journal of the American Academy of Dermatology, 1988, Volume: 18, Issue:1 Pt 2

    Herpes-associated erythema multiforme can be controlled by continuous suppressive treatment with oral acyclovir. Erythema multiforme is not prevented if oral acyclovir is administered after a herpes simplex recurrence is evident and it is of no value after erythema multiforme has occurred. There is some question whether continuous topical treatment with acyclovir to sites of recurrent herpes will sometimes prevent erythema multiforme. Erythema multiforme may be precipitated by orolabial and genital recurrences and by recurrences on skin of the buttocks and other sites. Some herpetic recurrences are associated with erythema multiforme and some are not and episodes of erythema multiforme are not always associated with clinical herpetic recurrences.

    Topics: Acyclovir; Erythema Multiforme; Herpes Simplex; Humans; Male; Recurrence

1988
Neonatal herpes simplex virus infection: relapse after initial therapy and transmission from a mother with an asymptomatic genital herpes infection and erythema multiforme.
    The Pediatric infectious disease journal, 1987, Volume: 6, Issue:11

    Topics: Acyclovir; Adult; Antibodies, Viral; Antibody Specificity; Combined Modality Therapy; Erythema Multiforme; Female; Herpes Genitalis; Herpes Simplex; Humans; Immunization, Passive; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Recurrence; Simplexvirus

1987
Successful use of oral acyclovir to prevent herpes simplex-associated erythema multiforme.
    The Journal of infection, 1987, Volume: 15, Issue:2

    Topics: Acyclovir; Erythema Multiforme; Female; Herpes Simplex; Humans; Middle Aged

1987
Oral acyclovir prevents herpes simplex virus-associated erythema multiforme.
    The British journal of dermatology, 1987, Volume: 116, Issue:1

    A young woman suffering from recurrent erythema multiforme associated with relapsing gluteal herpes simplex is presented, in whom long-term treatment with oral acyclovir prevented herpes episodes as well as erythema multiforme.

    Topics: Acyclovir; Administration, Oral; Adult; Erythema Multiforme; Female; Herpes Simplex; Humans

1987
[Preventive treatment with oral acyclovir of recurrent erythema multiforme, associated with herpes infection or not. Preliminary study].
    Annales de dermatologie et de venereologie, 1986, Volume: 113, Issue:3

    Topics: Acyclovir; Administration, Oral; Adult; Erythema Multiforme; Female; Herpesviridae Infections; Humans; Male; Middle Aged; Recurrence

1986
Erythema multiforme due to herpes simplex: treatment with oral acyclovir.
    Southern medical journal, 1986, Volume: 79, Issue:6

    We have reported a case of severe erythema multiforme caused by outbreaks of recurrent HSV-2 infection. The EM was debilitating and responded to the treatment of HSV with oral acyclovir. On stopping the oral acyclovir, the HSV and the EM both recurred. We recommend a trial of oral acyclovir in cases of severe EM caused by recurrent HSV.

    Topics: Acyclovir; Administration, Oral; Chronic Disease; Erythema Multiforme; Female; Herpes Simplex; Humans; Middle Aged; Recurrence

1986
Oral acyclovir for the prevention of herpes-associated erythema multiforme.
    Journal of the American Academy of Dermatology, 1986, Volume: 15, Issue:1

    Herpes simplex virus is the single most common precipitator of erythema multiforme. Typically, erythema multiforme lesions appear 10 to 14 days after a recurrent herpes simplex virus infection and attacks can be disabling when they occur at frequent intervals. Prior to the introduction of acyclovir (Zovirax), there was no effective therapy to prevent herpes-associated erythema multiforme. Four patients were treated with a maintenance dose of acyclovir for periods ranging from 10 to 26 months; there were no significant side effects from the drug and only one recurrence of erythema multiforme. Oral acyclovir may become the treatment of choice for herpes-associated erythema multiforme.

    Topics: Acyclovir; Adult; Erythema Multiforme; Female; Herpes Genitalis; Herpes Labialis; Herpes Simplex; Humans; Male; Recurrence

1986
Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir.
    Annals of internal medicine, 1985, Volume: 102, Issue:5

    Topics: Acyclovir; Administration, Oral; Adult; Drug Administration Schedule; Erythema Multiforme; Herpes Labialis; Humans; Male; Recurrence

1985
Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir.
    British medical journal (Clinical research ed.), 1981, Nov-21, Volume: 283, Issue:6303

    Topics: Acyclovir; Administration, Topical; Erythema Multiforme; Female; Guanine; Herpes Labialis; Humans; Middle Aged; Recurrence

1981
Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir.
    British medical journal (Clinical research ed.), 1981, Dec-05, Volume: 283, Issue:6305

    Topics: Acyclovir; Administration, Topical; Antiviral Agents; Erythema Multiforme; Guanine; Herpes Simplex; Humans

1981
chemdatabank.com